FDA Approves First Interchangeable Stelara Biosimilar
Amgen’s Wezlana is approved to treat multiple inflammatory diseases. It is expected to launch no later than Jan. 1, 2025
The FDA has approved a biosimilar that is interchangeable with Johnson & Johnson’s Stelara (ustekinumab). Amgen’s Wezlana (ustekinumab-auub) is approved to treat patients with multiple inflammatory diseases, including plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. Wezlana is expected to launch no later than Jan. 1, 2025, after an agreement with J&J.
Both products are monoclonal antibodies that binds to two cytokines, IL-12 and IL-23, that are involved in inflammatory and immune responses.
“Biosimilar medications offer additional safe and effective treatment options that have the potential to increase access for people requiring treatment for inflammatory diseases,” Nikolay Nikolov, M.D., director of the Office of Immunology and Inflammation in the FDA’s Center for Drug Evaluation and Research, said in a press release. “Today’s approval could have a meaningful impact for patients managing their disease.”
According to the FDA, the approval of Wezlana is based on a review of scientific evidence demonstrating that there are no clinically meaningful differences between the two products in terms of safety, purity and potency. This evidence included comparisons of the products on an analytical level using chemical and biological tests and biological assays that confirmed similarity in the structural and functional features.
Other expected Stelara biosimilars include:
- Alvotech and Teva’s AVT04, which is expected to launch no later Feb. 21, 2025. Last month, the FDA issued a complete response letter for AVT04 because of deficiencies in Alvotech’s Iceland, facility. The company plans to resubmit its application once these are addressed.
- Fesenius Kabi and Formycon plan to launch their biosimilar to Stelara, FYB202, no later than April 15, 2025.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
Trump Impact on Medicare Drug Price Negotiations Uncertain
Published: January 22nd 2025 | Updated: January 22nd 2025Trump has reversed some of President Biden’s initiatives, including $2 monthly out-of-pocket cap on some generics and experimental pricing models for gene therapies. But so far the healthcare elements of the Inflation Reduction Act remain unchanged.
Read More
FDA Approves Spravato Nasal Spray as a Standalone Treatment for Major Depressive Disorder
January 21st 2025One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it more difficult to be treated by traditional oral antidepressants.
Read More
